AstraZeneca PLC (LSE:AZN) has agreed to invest $2bn in newly issued Summit Therapeutics shares and to run a jointly funded trial pairing its antibody-drug conjugate sonesitatug vedotin with Summit's PD-1/VEGF bispecific antibody ivonescimab in gastrointestinal cancers. The two companies also signed a memorandum of understanding on a wider development programme.

What was announced

In an announcement on 29 September 2026, AstraZeneca set out two linked agreements with Summit Therapeutics Inc. The first is a $2bn strategic Investment in newly issued Summit stock. The second is a clinical collaboration to test Sone-Ve with ivonescimab in gastrointestinal cancers.

The companies also executed a memorandum of understanding to pursue a broader global development programme. This would combine ivonescimab with medicines from AstraZeneca's oncology portfolio, including other antibody-drug conjugates (ADCs). The announcement does not set out a timetable, budget or binding terms for this programme.

The numbers

AstraZeneca will receive about 109,000 shares of Summit preferred stock. Each is convertible into 1,000 shares of common stock, giving about 109 million common shares on conversion. The stake is equivalent to about 12.0% of Summit's outstanding common stock, or about 10.6% on a fully diluted basis. Conversion into common stock is subject to customary regulatory clearances. Closing of the investment is expected within one week of the announcement.

The announcement does not give a price per share or a premium to Summit's market price. Based on the disclosed figures, $2bn divided by about 109 million common-equivalent shares works out at roughly $18.35 per common share. This figure is derived, not disclosed.

Several terms are not addressed, including any board seat for AstraZeneca, standstill or lock-up arrangements, and any effect on AstraZeneca's financial guidance.

Background

Ivonescimab is described as a first-in-class bispecific antibody targeting PD-1 and VEGF. It was engineered by Akeso Inc. Summit holds exclusive development and commercialisation rights outside China, while Akeso keeps the rights in China and certain other regions. The drug is approved in China for certain patients with non-small cell lung cancer (NSCLC). In the US, a Biologics License Application for EGFR-mutated NSCLC is under review by the FDA. Phase III trials are running in several cancer types, including lung, bladder, breast, head and neck, colorectal and pancreatic cancers.

Sone-Ve is AstraZeneca's Claudin-18.2-targeting ADC with an MMAE payload. The announcement says it recently showed a statistically significant improvement in overall survival in the CLARITY-Gastric01 trial, in second-line and later gastric cancer.

Under the collaboration, each company supplies its own medicine and the two share the trial costs. Each keeps independent development and commercial rights to its own product, so the deal is not a licensing agreement for either drug.

Susan Galbraith, AstraZeneca's Executive Vice President, Oncology Haematology R&D, said: "A core pillar of our oncology strategy is to broaden the reach of our ADC portfolio as the backbone of treatment across tumour types with combinations alongside next-generation immunotherapies." Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics, said the developments "open an exciting new chapter in the advancement of ivonescimab."

What to watch next

The first milestone is closing of the share investment, expected within a week, followed by the regulatory clearances needed to convert the preferred stock into common stock. The announcement gives no design or start date for the Sone-Ve and ivonescimab gastrointestinal trial. It is also not yet known whether the memorandum of understanding becomes a definitive agreement covering other AstraZeneca (LSE:AZN) medicines.

Regulatory events for the two drugs are also relevant. These include the FDA's review of ivonescimab in EGFR-mutated NSCLC and the progress of Sone-Ve after the CLARITY-Gastric01 result. The announcement does not say whether AstraZeneca might increase its stake or deepen the relationship beyond the terms disclosed.